Clinical Trials Logo

Clinical Trial Summary

This study will evaluate marking and distention of the bowel of the oral contrast agent, NX9, at CT of the abdomen and pelvis, VLDCT with no contrast will be followed by VLDCT with NX9 contrast followed by CT with NX9 and standard IV contrast. Eligible subjects will have cancer or other GI disorders for which CT is typically used to assess their disease. This is an open label study with efficacy evaluated in a masked fashion following completion of the entire study. Results of the NX9 scans will not be used for treatment decisions. PK will be evaluated in a subset of subjects at a single center.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04789200
Study type Interventional
Source Nextrast, Inc.
Contact
Status Completed
Phase Phase 2
Start date August 1, 2020
Completion date December 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT05654909 - Prehospital Assessment Units - a Matched Cohort Study
Not yet recruiting NCT06200961 - Trans-nasal Endoscopy for Bariatric Patients N/A
Recruiting NCT06376695 - Radicle GI Health 24: A Study of Health and Wellness Products on GI Health and Related Health Outcomes N/A
Recruiting NCT05725954 - GUT LINK: A Study of a Care Pathway Across Primary and GI Specialty Care N/A
Completed NCT06009614 - Radicle GI Health: A Study of Health and Wellness Products on GI Health and Other Health Outcomes N/A